Outcome and Clinical Significance of Immunophenotypic Markers Expressed in different treatment protocols of T-ALL Pediatric Patients in developing countries

Abstract Background T-ALL accounts for about 15% of pediatric ALL. With wider use of intensive chemotherapy, the prognosis for childhood T-ALL has improved. Further gains in treatment outcome will likely require methods to identify patients who continue to fail on contemporary protocols. This study aimed to evaluate pediatric patients had T-ALL at two different Arabic cancer centers regarding their clinic-pathologic, immunophenotypic and cytogenetic features and outcome. Patients and Methods Retrospective study included all children with T-ALL treated between 2003 and 2013 at two oncology centers in Middle East. Patients divided into (group I) treated with BFM-90 treatment protocol between February 2003& June 2007 and (group II) includes all patients treated thereafter by the total therapy study XIII protocol for high-risk ALL. Results Study included 103 patients with median age of 8.9 years. Male to female ratio was 2.6:1. The median initial WBCs was 123x109/L. CNS leukemia detected in 15%. ETP-ALL phenotype found in16.5%. 5year-OS was 20.7%±67.5% and 72.9%±5.7% (p